Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T Cells, potentiated by liposomal alendronic acid

Journal of Immunology

Volumn 193, Issue 11, 2014, Pages 5557-5566

  Parente Pereira, Ana C ^a   Shmeeda, Hilary ^b   Whilding, Lynsey M ^a,c   Zambirinis, Constantinos P ^a   Foster, Julie ^d   Van Der Stegen, Sjoukje J C ^a   Beatson, Richard ^a   Zabinski, Tomasz ^a   Brewig, Nancy ^c   Sosabowski, Jane K ^d   Mather, Stephen ^d   Ghaem Maghami, Sadaf ^c   Gabizon, Alberto ^b,e   Maher, John ^a,f,g  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e HEBREW UNIVERSITY   (Israel)

^f BARNET HOSPITAL   (United Kingdom)

^g KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; FOLATE RECEPTOR; GAMMA INTERFERON; LIPOSOME; ZOLEDRONIC ACID; LYMPHOCYTE ANTIGEN RECEPTOR; T-CELL RECEPTOR VDELTA2, HUMAN; T-CELL RECEPTOR VGAMMA9, HUMAN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SENSITIZATION; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; TUMOR CELL CULTURE; TUMOR IMMUNITY; TUMOR REGRESSION; ANIMAL; CARCINOMA; CHEMISTRY; CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; IMMUNIZATION; IMMUNOLOGY; METABOLISM; OVARIAN NEOPLASMS; PROCEDURES; SCID MOUSE; TRANSPLANTATION; TUMOR CELL LINE; TUMOR VOLUME;

ALENDRONATE; ANIMALS; CARCINOMA; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; LIPOSOMES; MICE; MICE, SCID; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84912569812     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402200     Document Type: Article

References (37)

1. Gober, H. J., M. Kistowska, L. Angman, P. Jenö, L. Mori, and G. De Libero. 2003. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197: 163-168.
2. Clendening, J. W., A. Pandyra, P. C. Boutros, S. El Ghamrasni, F. Khosravi, G. A. Trentin, A. Martirosyan, A. Hakem, R. Hakem, I. Jurisica, and L. Z. Penn. 2010. Dysregulation of the mevalonate pathway promotes transformation. Proc. Natl. Acad. Sci. USA 107: 15051-15056.
3. Brennan, D. J., J. Brändstedt, E. Rexhepaj, M. Foley, F. Pontén, M. Uhlén, W. M. Gallagher, D. P. O'Connor, C. O'Herlihy, and K. Jirstrom. 2010. Tumourspecific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer 10: 125.
4. Mathew, A., and A. Brufsky. 2014. Bisphosphonates in breast cancer. Int. J. Cancer 10.1002/ijc.28965.
5. Fournié, J. J., H. Sicard, M. Poupot, C. Bezombes, A. Blanc, F. Romagné, L. Ysebaert, and G. Laurent. 2013. What lessons can be learned from gd T cellbased cancer immunotherapy trials? Cell. Mol. Immunol. 10: 35-41.
6. Mönkkönen, H., J. Kuokkanen, I. Holen, A. Evans, D. V. Lefley, M. Jauhiainen, S. Auriola, and J. Mönkkönen. 2008. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 19: 391-399.
7. Mattarollo, S. R., T. Kenna, M. Nieda, and A. J. Nicol. 2007. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol. Immunother. 56: 1285-1297.
8. Lavoué, V., F. Cabillic, O. Toutirais, A. Thedrez, B. Dessarthe, C. T. de La Pintière, P. Daniel, F. Foucher, E. Bauville, S. Henno, et al. 2012. Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy. Int. J. Cancer 131: E449-E462.
9. Benzaïd, I., H. Mönkkönen, V. Stresing, E. Bonnelye, J. Green, J. Mönkkönen, J. L. Touraine, and P. Clézardin. 2011. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 71: 4562-4572.
10. Shmeeda, H., Y. Amitay, J. Gorin, D. Tzemach, L. Mak, J. Ogorka, S. Kumar, J. A. Zhang, and A. Gabizon. 2010. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J. Control. Release 146: 76-83.
11. Shmeeda, H., S. Even-Chen, R. Honen, R. Cohen, C. Weintraub, and Y. Barenholz. 2003. Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies. Methods Enzymol. 367: 272-292.
12. Wilkie, S., S. E. Burbridge, L. Chiapero-Stanke, A. C. Pereira, S. Cleary, S. J. van der Stegen, J. F. Spicer, D. M. Davies, and J. Maher. 2010. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285: 25538-25544.
13. Parente-Pereira, A. C., L. M. Whilding, N. Brewig, S. J. van der Stegen, D. M. Davies, S. Wilkie, M. C. van Schalkwyk, S. Ghaem-Maghami, and J. Maher. 2013. Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin. J. Immunol. 191: 2437-2445.
14. Yu, J. 2011. Zoledronate activates NK cells. Blood 118: 2642-2643.
15. Dyall, S., S. A. Gayther, and D. Dafou. 2010. Cancer stem cells and epithelial ovarian cancer. J. Oncol. 2010: 105269.
16. Shmeeda, H., Y. Amitay, D. Tzemach, J. Gorin, and A. Gabizon. 2013. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. J. Control. Release 167: 265-275.
17. Zhang, L., J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348: 203-213.
18. Lu, J., R. Aggarwal, S. Kanji, M. Das, M. Joseph, V. Pompili, and H. Das. 2011. Human ovarian tumor cells escape gd T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules. PLoS ONE 6: e23348.
19. Kong, Y., W. Cao, X. Xi, C. Ma, L. Cui, and W. He. 2009. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood 114: 310-317.
20. Vantourout, P., C. Willcox, A. Turner, C. M. Swanson, Y. Haque, O. Sobolev, A. Grigoriadis, A. Tutt, and A. Hayday. 2014. Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway. Sci. Transl. Med. 6: 231ra249.
21. Zheng, B. J., K. W. Chan, S. Im, D. Chua, J. S. Sham, P. C. Tin, Z. M. He, and M. H. Ng. 2001. Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int. J. Cancer 92: 421-425.
22. Beck, B. H., H. G. Kim, H. Kim, S. Samuel, Z. Liu, R. Shrestha, H. Haines, K. Zinn, and R. D. Lopez. 2010. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res. Treat. 122: 135-144.
23. Di Carlo, E., P. Bocca, L. Emionite, M. Cilli, G. Cipollone, F. Morandi, L. Raffaghello, V. Pistoia, and I. Prigione. 2013. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma. Mol. Ther. 21: 1034-1043.
24. Santolaria, T., M. Robard, A. Léger, V. Catros, M. Bonneville, and E. Scotet. 2013. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo. J. Immunol. 191: 1993-2000.
25. Gertner-Dardenne, J., R. Castellano, E. Mamessier, S. Garbit, E. Kochbati, A. Etienne, A. Charbonnier, Y. Collette, N. Vey, and D. Olive. 2012. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. J. Immunol. 188: 4701-4708.
26. Kabelitz, D., D. Wesch, E. Pitters, and M. Zöller. 2004. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J. Immunol. 173: 6767-6776.
27. Sato, K., S. Kimura, H. Segawa, A. Yokota, S. Matsumoto, J. Kuroda, M. Nogawa, T. Yuasa, Y. Kiyono, H. Wada, and T. Maekawa. 2005. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer 116: 94-99.
28. Dunford, J. E., K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, and M. J. Rogers. 2001. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296: 235-242.
29. Gabizon, A. A., H. Shmeeda, and S. Zalipsky. 2006. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 16: 175-183.
30. Prabhakar, U., H. Maeda, R. K. Jain, E. M. Sevick-Muraca, W. Zamboni, O. C. Farokhzad, S. T. Barry, A. Gabizon, P. Grodzinski, and D. C. Blakey. 2013. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73: 2412-2417.
31. Gabizon, A., H. Shmeeda, and T. Grenader. 2012. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur. J. Pharm. Sci. 45: 388-398.
32. Turk, M. J., D. J. Waters, and P. S. Low. 2004. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 213: 165-172.
33. van der Stegen, S. J., D. M. Davies, S. Wilkie, J. Foster, J. K. Sosabowski, J. Burnet, L. M. Whilding, R. M. Petrovic, S. Ghaem-Maghami, S. Mather, et al. 2013. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J. Immunol. 191: 4589-4598.
34. Gabizon, A., A. T. Horowitz, D. Goren, D. Tzemach, H. Shmeeda, and S. Zalipsky. 2003. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 9: 6551-6559.
35. Dieli, F., F. Poccia, M. Lipp, G. Sireci, N. Caccamo, C. Di Sano, and A. Salerno. 2003. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J. Exp. Med. 198: 391-397.
36. Wilhelm, M., M. Smetak, K. Schaefer-Eckart, B. Kimmel, J. Birkmann, H. Einsele, and V. Kunzmann. 2014. Successful adoptive transfer and in vivo expansion of haploidentical gd T cells. J. Transl. Med. 12: 45.
37. Deniger, D. C., S. Maiti, T. Mi, K. Switzer, V. Ramachandran, L. V. Hurton, S. Ang, S. Olivares, B. A. Rabinovich, H. Huls, et al. 2014. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin. Cancer Res. pii: clincanres.3451.2013.